Research programme: peptide cancer vaccines - Strike Pharma

Alternative Names: STRIKE 2001 peptide vaccine; STRIKE-2001

Latest Information Update: 21 Feb 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Strike Pharma
Class Cancer vaccines; Drug conjugates; Immunoconjugates; Immunoglobulin Fv fragments; Monoclonal antibodies; Peptide vaccines; Recombinant fusion proteins
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

19 Feb 2024 Strike Pharma plans a phase I trial for peptide cancer vaccines for Cancer (Strike Pharma pipeline, February 2024)
20 Sep 2023 Preclinical trials in Cancer in Sweden (SC)
20 Sep 2023 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical studies presented at the 7^th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com